


Myelodysplastic syndrome with occult diffuse large B-cell lymphoma

Ja Young Lee¹, Hwa Jin Cho²

Departments of¹Laboratory Medicine, ²Pathology, Inje University College of Medicine, Busan, Korea

Received on February 28, 2017; Revised on March 22, 2017; Accepted on June 15, 2017

Correspondence to Ja Young Lee, M.D., Department of Laboratory Medicine, Busan Paik Hospital, Inje University, College of Medicine, 75, Bokji-ro, Busanjin-gu, Busan 47392, Korea, E-mail: liring@hanmail.net



A 71-year-old woman was admitted with dyspnea and generalized weakness. Twenty months prior, she had been diagnosed with myelodysplastic syndrome (MDS) with multilineage dysplasia. (A, Bone marrow (BM) aspiration, Wright-Giemsa stain, $\times 1,000$). She was given eight cycles of azacitidine chemotherapy with regular follow-up. On admission, complete blood count revealed pancytopenia with a hemoglobin (Hb) level of 4.9 g/dL, white blood cell (WBC) count of $2.54 \times 10^9/L$ (32% neutrophils, 43% lymphocytes, and 25% monocytes), and platelet count of $7 \times 10^9/L$. The BM examination showed hypercellularity with lymphoid hyperplasia. (B, BM aspiration, Wright-Giemsa stain, $\times 1,000$, black arrow; C, BM biopsy, Hematoxylin and eosin stain, $\times 100$). Flow cytometric analysis showed increased number of B lymphocytes expressing CD19, CD20 and CD22. Immunohistochemistry of the BM biopsy revealed neoplastic cells positive for CD20 (C, lower left inset) and MUM-1, and negative for CD23, bcl-2, bcl-6 and cyclin D1. This was consistent with BM involvement in diffuse large B-cell lymphoma (DLBCL). Cytogenetic analysis revealed that normal karyotype at initial BM was changed to trisomy 3 in 11/20 metaphases. Clonal *IGH* and *IGK* gene rearrangements were found in this specimen (D), and identically rearranged genes were found at initial diagnosis. Therefore, the patient was diagnosed with MDS with occult DLBCL.